JAGSONPAL PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 328.4 INR | +0.66% |
|
-1.17% | -15.56% |
| May. 24 | Jagsonpal Launches Drug for Vasomotor Symptoms; Shares Jump 5% | MT |
| May. 24 | Jagsonpal Launches Memup India's First Bioidentical Hormone Replacement Therapy in A Single Pill | CI |
| Sales 2022 | 2.26B 27.1M | Sales 2023 | 2.37B 28.38M | Capitalization | 7.59B 91.02M |
|---|---|---|---|---|---|
| Net income 2022 | 196M 2.35M | Net income 2023 | 267M 3.2M | EV / Sales 2022 | 3.42 x |
| Net cash position 2022 | 482M 5.77M | Net cash position 2023 | 1.09B 13.02M | EV / Sales 2023 | 2.75 x |
| P/E ratio 2022 |
41.9
x | P/E ratio 2023 |
28.4
x | Employees | 940 |
| Yield 2022 |
1.28% | Yield 2023 |
1.73% | Free-Float | 24.12% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.66% | ||
| 1 week | -1.17% | ||
| Current month | +0.71% | ||
| 1 month | -4.40% | ||
| 3 months | +6.59% | ||
| 6 months | -20.80% | ||
| Current year | -15.56% |
1 week
275.00
340.00
1 month
275.00375.50
Current year
273.60412.00
1 year
273.60514.85
3 years
121.10514.85
5 years
16.25514.85
10 years
14.50514.85
| Managers | Title | Age | Since |
|---|---|---|---|
Manish Gupta
CEO | Chief Executive Officer | - | 22-07-15 |
Abhishek Joshi
CMP | Compliance Officer | - | 23-02-12 |
| Director/Board Member | 67 | 78-08-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 78-08-16 | |
Harsha Raghavan
CHM | Chairman | 52 | 22-06-28 |
Manish Gupta
CEO | Chief Executive Officer | - | 22-07-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 328.4 | +0.66% | 31,574 |
| 24-06-05 | 326.2 | +8.61% | 44,516 |
| 24-06-04 | 300.4 | -7.54% | 43,894 |
| 24-06-03 | 324.9 | -0.37% | 20,511 |
| 24-05-31 | 326.1 | -1.87% | 53,293 |
Delayed Quote NSE India S.E., June 06, 2024 at 07:43 am EDT
More quotes
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Companyâs therapy areas include gynecology, orthopedics, and others.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.56% | 103M | |
| +43.64% | 749B | |
| +39.42% | 605B | |
| -6.58% | 351B | |
| +19.72% | 328B | |
| +8.78% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.03% | 167B | |
| +6.13% | 165B |
- Stock Market
- Equities
- JAGSNPHARM Stock
